NEW YORK (GenomeWeb News) – Asuragen today said that it has entered into an exclusive collaboration with Novartis to develop tools intended to aid laboratories with standardization of BCR-ABL1 RT-qPCR testing to the international scale.
The Austin, Texas-based firm said that it would distribute the Armored RNA Quant BCR-ABL1 RNA International Scale calibrators and software reporting tools directly or through distributors worldwide.
"Our development of the BCR-ABL1 RNA IS Calibrators and software tool leverages both our expertise in molecular diagnostic assay development and our proprietary Armored RNA technology," Asuragen President Rollie Carlson noted in a statement.
Asuragen said that the calibrators are intended to be compatible with "several widely used assays, including both commercially available and laboratory developed tests."
Financial and other terms of the alliance were not disclosed.